Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>US cap-weighted Health Care (ETF: XLV-US) remains in a 4.5-month RS uptrend relative to the S&amp;P 500, and we have the Sector on watch for a potential upgrade to overweight.</li>
<li>The VanEck Pharmaceutical ETF (PPH-US) recently broke out topside a 9-month base and RS displays a bullish reversal. Zooming-out, we can see a 6+ year base breakout.</li>
<li>Buy: Eli Lilly (LLY-US), Astrazeneca (AZN-US), Novo Nordisk (NOVO.B-DK), Roche (ROG-CH), Bristol-Myers Squibb (BMY-US), Bayer AG (BAYN-DE), UCB S.A. (UCB-BE), Ipsen SA (IPN-FR), ONO Pharmaceutical (4528-JP), and Teva Pharmaceutical (TEVA-US)</li>
</ul>


US cap-weighted Health Care (ETF: XLV-US) remains in a 4.5-month RS uptrend relative to the S&amp;P 500, and we have the Sector on watch for a potential upgrade to overweight.
The VanEck Pharmaceutical ETF (PPH-US) recently broke out topside a 9-month base and RS displays a bullish reversal. Zooming-out, we can see a 6+ year base breakout.
Buy: Eli Lilly (LLY-US), Astrazeneca (AZN-US), Novo Nordisk (NOVO.B-DK), Roche (ROG-CH), Bristol-Myers Squibb (BMY-US), Bayer AG (BAYN-DE), UCB S.A. (UCB-BE), Ipsen SA (IPN-FR), ONO Pharmaceutical (4528-JP), and Teva Pharmaceutical (TEVA-US)


Buy Global LargeCap Pharma: LLY, AZN, NOVO.B-DK, ROG-CH, BMY, BAYN-DE, UCB-BE, IPN-FR, 4528-JP, TEVA

<ul>
<li>We continue to see some encouraging signs that suggest that the lows may have been established for this correction.</li>
<li>We still believe a bottoming process would likely take weeks or potentially months and could come with more tests of the lows -- or even an undercut.</li>
<li>With that said, we continue to see attractive and actionable setups, primarily within cyclical value (Energy, Materials, Manufacturing, Transportation, and Financials).</li>
</ul>


We continue to see some encouraging signs that suggest that the lows may have been established for this correction.
We still believe a bottoming process would likely take weeks or potentially months and could come with more tests of the lows -- or even an undercut.
With that said, we continue to see attractive and actionable setups, primarily within cyclical value (Energy, Materials, Manufacturing, Transportation, and Financials).


Encouraging Signs, But Concerns Still Outweigh; Buying Materials, Energy, Industrials, Health Care

Chief Economist & Political Strategist, CrossASEAN Research

Prasenjit K. Basu

Chief Economist & Political Strategist

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Macroeconomics

<ul>
<li>Germany, the EU's most consequential power, now has a "traffic-lights" coalition government with an ambitious agenda for its structural transformation into a green, digitized economy. </li>
<li>Socially-Liberal policies, including expunging 'race" from the constitution, will allow greater entry of technology professionals, and relatively smooth path toward citizenship, which should attract considerable talent. </li>
<li>With the debt brake absent in 2022, the state railway and development bank will borrow big to fund the investment surge, lowering Germany's current account surplus and boosting Eurozone growth. </li>
</ul>


Germany, the EU's most consequential power, now has a "traffic-lights" coalition government with an ambitious agenda for its structural transformation into a green, digitized economy. 
Socially-Liberal policies, including expunging 'race" from the constitution, will allow greater entry of technology professionals, and relatively smooth path toward citizenship, which should attract considerable talent. 
With the debt brake absent in 2022, the state railway and development bank will borrow big to fund the investment surge, lowering Germany's current account surplus and boosting Eurozone growth. 


Germany: Scholz-Led Traffic-Light Coalition to Redefine Left-Wing Pragmatism

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Independent Stock Specific Research

BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Equity Bottom-Up

<ul type="disc"><li>There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily.</li></ul> <ul type="disc"><li>The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny.</li></ul> <ul type="disc"><li>VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results.</li></ul> <ul type="disc"><li>We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.</li></ul>

There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily. The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny. VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results. We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<a href="https://www.smartkarma.com/entities/pharmasgp-gmbh" target="_blank" data-smartkarma-citation="entities:29009:1" rel="noopener">PharmaSGP (1780644D GR)</a> is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (OTC) and other healthcare products. PharmaSGP has launched an IPO on the Frankfurt Stock Exchange at a price range of €31.50-36.50 per share. The offer, which a purely a secondary raise, will raise gross proceeds of €304.3-352.6 million for the selling shareholders. The book-building process is expected to end on 18 June, with trading expected to commence on 19 June.<div class="content-highlight">PharmaSGP is a play on the chemical-free OTC market in Continental Europe which is growing due to the ageing of the population, a trend towards self-medication and the growing demand for natural remedies. Overall, PharmaSGP offers strong fundamentals at an attractive valuation, in our view.</div>

PharmaSGP (1780644D GR) is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (OTC) and other healthcare products. PharmaSGP has launched an IPO on the Frankfurt Stock Exchange at a price range of €31.50-36.50 per share. The offer, which a purely a secondary raise, will raise gross proceeds of €304.3-352.6 million for the selling shareholders. The book-building process is expected to end on 18 June, with trading expected to commence on 19 June.PharmaSGP is a play on the chemical-free OTC market in Continental Europe which is growing due to the ageing of the population, a trend towards self-medication and the growing demand for natural remedies. Overall, PharmaSGP offers strong fundamentals at an attractive valuation, in our view.

PharmaSGP IPO Initiation: Potent Medicine

Germany

Bayer AG produces and markets healthcare and agricultural products. The Company manufactures products that include aspirin, antibiotics, anti-infectives, cardiovascular, oncology, central nervous system drugs, over-the-counter medications, diagnostics, and animal health products, as well as crop protection products, plastics, and polyurethanes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bayer (BAYN GR)

Buy Global LargeCap Pharma: LLY, AZN, NOVO.B-DK, ROG-CH, BMY, BAYN-DE, UCB-BE, IPN-FR, 4528-JP, TEVA

The VanEck Pharmaceutical ETF $PPH recently broke out topside a 9-month base and RS displays a bullish reversal. Zooming-out, we can see a 6+ year...

Vermilion Research

Encouraging Signs, But Concerns Still Outweigh; Buying Materials, Energy, Industrials, Health Care

We continue to see some encouraging signs that suggest that the lows may have been established for this correction. Still, cyclical value remains...

Vermilion Research

Germany: Scholz-Led Traffic-Light Coalition to Redefine Left-Wing Pragmatism

The new coalition will borrow in 2022, & invest in a green, digital transformation over the next 5 years. Germany's large current account surplus...

Prasenjit K. Basu

PLXP: Headlines to Buy

News headlines of medical opinion on taking aspirin daily should be construed as a positive for PLXP and its drug VAZALORE. Negative opinion on...

BWS Financial Inc

PharmaSGP IPO Initiation: Potent Medicine

PharmaSGP (1780644D GR) is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)